Menü
sharewise sharewise
Einloggen
Registrieren
Einloggen
Registrieren
Microsoft selbst warnt vor der Verwendung von Internet Explorer, da er nicht mehr den neuesten Web- und Sicherheitsstandards entspricht. Wir können daher nicht garantieren, dass die Seite im Internet Explorer in vollem Umfang funktioniert. Nutze bitte Chrome oder Firefox.

Erstellt von ElectricPlayer 

Cara Therapeutics Inc. diskutieren

Cara Therapeutics Inc.

WKN: A1XDTK / Symbol: CARA / Name: Cara / Aktie / Biotechnologie & medizinische Forschung / Small Cap /

0,64 €
3,59 %

8 1
8
1

Sell Cara Therapeutics Inc.

ElectricPlayer 
0
Melden Teilen
29.01.21 Sell -33,57 %

Cara Therapeutics, Inc. (NASDAQ: CARA) was downgraded by analysts at Bank of America Co. from a "neutral" rating to an "underperform" rating.
Ratings data for CARA provided by MarketBeat

Bank of America Co. 
0
Melden Teilen
07.03.23 Sell -84,51 %
Einschätzung Buy
Rendite (%) -81,49 %
Kursziel 20,09
Veränderung
Endet am 04.04.24

Cara Therapeutics, Inc. (NASDAQ: CARA) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $22.00 price target on the stock.
Ratings data for CARA provided by MarketBeat

Needham & Company LLC 
0
Melden Teilen
04.04.23
Einschätzung Buy
Rendite (%) -77,40 %
Kursziel 20,10
Veränderung
Endet am 08.08.24

Cara Therapeutics, Inc. (NASDAQ: CARA) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $22.00 price target on the stock.
Ratings data for CARA provided by MarketBeat

Needham & Company LLC 
0
Melden Teilen
08.08.23
Einschätzung Buy
Rendite (%) -49,57 %
Kursziel 6,62
Veränderung
Endet am 19.10.24

Cara Therapeutics, Inc. (NASDAQ: CARA) had its price target lowered by analysts at HC Wainwright from $15.00 to $7.00. They now have a "buy" rating on the stock.
Ratings data for CARA provided by MarketBeat

HC Wainwright 
0
Melden Teilen
19.10.23
Einschätzung Buy
Rendite (%) 13,62 %
Kursziel 5,50
Veränderung
Endet am 18.12.24

Cara Therapeutics, Inc. (NASDAQ: CARA) had its price target lowered by analysts at Needham & Company LLC from $22.00 to $6.00. They now have a "buy" rating on the stock.
Ratings data for CARA provided by MarketBeat

Needham & Company LLC 
0
Melden Teilen
18.12.23
Einschätzung Buy
Rendite (%) 12,32 %
Kursziel 2,28
Veränderung
Endet am 19.12.24

Cara Therapeutics, Inc. (NASDAQ: CARA) had its price target lowered by analysts at HC Wainwright from $7.00 to $2.50. They now have a "buy" rating on the stock.
Ratings data for CARA provided by MarketBeat

HC Wainwright 
0
Melden Teilen
19.12.23
Einschätzung Buy
Rendite (%) 25,10 %
Kursziel 4,59
Veränderung
Endet am 22.01.25

Cara Therapeutics, Inc. (NASDAQ: CARA) had its price target lowered by analysts at Needham & Company LLC from $6.00 to $5.00. They now have a "buy" rating on the stock.
Ratings data for CARA provided by MarketBeat

Needham & Company LLC 
0
Melden Teilen
22.01.24

Cara Therapeutics, Inc. (NASDAQ: CARA) was downgraded by analysts at StockNews.com from a "hold" rating to a "sell" rating.
Ratings data for CARA provided by MarketBeat

StockNews.com 
0
Melden Teilen
17.02.24 Sell 9,61 %
Einschätzung Buy
Rendite (%) -17,78 %
Kursziel 4,61
Veränderung
Endet am 05.03.25

Cara Therapeutics, Inc. (NASDAQ: CARA) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $5.00 price target on the stock.
Ratings data for CARA provided by MarketBeat

Needham & Company LLC 
0
Melden Teilen
05.03.24
Einschätzung Buy
Rendite (%) -26,37 %
Kursziel 4,62
Veränderung
Endet am 28.03.25

Cara Therapeutics, Inc. (NASDAQ: CARA) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $5.00 price target on the stock.
Ratings data for CARA provided by MarketBeat

Needham & Company LLC 
0
Melden Teilen
28.03.24
Einschätzung Buy
Rendite (%) -21,32 %
Kursziel 4,64
Veränderung
Endet am 10.04.25

Cara Therapeutics, Inc. (NASDAQ: CARA) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $5.00 price target on the stock.
Ratings data for CARA provided by MarketBeat

Needham & Company LLC 
0
Melden Teilen
10.04.24
Noch kein Mitglied? Jetzt kostenlos registrieren!

Neueste Beiträge

StockNews_com in Tutor Perini Corp. diskutieren
Tutor Perini Co. (NYSE: TPC) was upgraded by analysts at...
27.04.24
StockNews_com in Ambarella Inc. diskutieren
Ambarella, Inc. (NASDAQ: AMBA) was upgraded by analysts ...
27.04.24
StockNews_com in Amerisafe Inc. diskutieren
AMERISAFE, Inc. (NASDAQ: AMSF) was downgraded by analyst...
27.04.24
StockNews_com in Kopin Corp. diskutieren
Kopin Co. (NASDAQ: KOPN) was upgraded by analysts at Sto...
27.04.24
StockNews_com in MGP Ingredients Inc. diskutieren
MGP Ingredients, Inc. (NASDAQ: MGPI) was downgraded by a...
27.04.24
StockNews_com in Newtek Business Services Inc. diskutieren
NewtekOne, Inc. (NASDAQ: NEWT) was downgraded by analyst...
27.04.24
StockNews_com in Hudson Global Inc. diskutieren
Hudson Global, Inc. (NASDAQ: HSON) is now covered by ana...
27.04.24
StockNews_com in Lipocine Inc diskutieren
Lipocine Inc. (NASDAQ: LPCN) is now covered by analysts ...
27.04.24
Mehr anzeigen